FDA approves Prior Approval Supplement for EMBEDA Extended Release Capsules CII

Download PDF Copy

Nov 4 2013

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved a Prior Approval Supplement for EMBEDA^® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII.

The Prior Approval Supplement included an update to the EMBEDA manufacturing process that addressed the pre-specified stability requirement that led to the voluntary recall of EMBEDA from the market in March 2011. Pfizer anticipates product availability in the second quarter of 2014.

Source:

Pfizer Inc.

Posted in: Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Mediterranean diet during pregnancy cuts babies’ food allergy risk

Food insecurity raises long COVID risk while SNAP support cuts it

How food choices and cooking methods drive brain inflammation and disease

Can a short message change how we think about expired food?

New gluten test detects hidden wheat in food in under three minutes

Asthma and multiple allergies raise the risk of failed oral food challenges

Fast food’s grip on American diets weakens as younger adults cut back

Common food additives may trigger childhood asthma

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.